Orion negotiated a collaboration agreement with Finnish company DelSiTech through which Orion will be able to combine DelSiTech’s drug delivery technology with its own drug molecules. DelSiTech will receive milestone and project work-related payments.

The DelSiTech technology has been developed to enable the controlled delivery of a wide range of active ingredients including proteins and even labile viruses. It is based on a silica matrix into which the active ingredient is embedded and can be designed to degrade at a predetermined rate for the controlled release of active molecules.

Previous articleOff-label Marketing and a Lesson in Integrity
Next articleNovartis Nabs Global Commercialization Rights to Paratek’s Late-Stage Antibiotic